Navigating All the Doses of Wegovy for Your Weight Management Journey

Last reviewed: July 8, 2026

Last updated: July 8, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Wegovy is not one dose — it is a family of strengths, and the current FDA prescribing information lists six of them for the injection: single-dose prefilled pens of 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg and 7.2 mg, with single-dose prefilled syringes available from 0.25 mg up to 2.4 mg. Wegovy is also supplied as tablets in 1.5 mg, 4 mg, 9 mg and 25 mg. Which of those applies to you is a decision your prescriber makes and your pharmacy label records. What follows is what the strengths are and why the label is built this way — not instructions for changing anything yourself.

The Strengths That Exist

The Dosage Forms and Strengths section of a label is a product inventory, and Wegovy's is unusually long for a single brand. On the injection side, six pen strengths span a nearly thirtyfold range from 0.25 mg to 7.2 mg. The prefilled syringe presentations stop at 2.4 mg; the 7.2 mg strength, marketed as Wegovy HD, is a pen-only presentation.

The tablet line is a separate architecture entirely. Oral semaglutide for weight management is supplied in 1.5 mg, 4 mg, 9 mg and 25 mg tablets — numbers that look nothing like the injection strengths because an orally administered peptide is absorbed very differently from a subcutaneous one. Comparing a 25 mg tablet to a 2.4 mg injection as though the larger number means a larger effect is a category error.

Why a Label Needs This Many Steps

The strengths exist to support gradual dose escalation, and the reason is tolerability rather than efficacy. The Wegovy label reports that gastrointestinal adverse reactions "were most frequently reported during dosage escalation," and the adverse reaction table for the 2.4 mg injection lists nausea in 44% of patients versus 16% on placebo, diarrhea in 30% versus 16%, vomiting in 24% versus 6%, and constipation in 24% versus 11%.

Those numbers are why the lower strengths are manufactured at all. A schedule that stepped straight to a maintenance strength would push more people out of treatment early. The label records that 6.8% of patients on Wegovy 2.4 mg injection and 3.2% on placebo permanently discontinued because of adverse reactions, with nausea, vomiting and diarrhea the most common reasons — and that is with escalation built in.

Not Every Strength Is a Destination

The labeling distinguishes between strengths used on the way up and strengths intended to be maintained. For weight reduction, the label identifies 1.7 mg or 2.4 mg once weekly as maintenance options with 2.4 mg described as recommended, and 7.2 mg once weekly as the maximum for additional weight reduction in adults. For cardiovascular risk reduction, the maintenance framing again centers on 2.4 mg with 1.7 mg as an alternative.

This is why "what dose are you on?" is a poorer question than it sounds. Someone at 1 mg in week ten and someone maintained at 1.7 mg indefinitely are in completely different situations, and neither is behind or ahead of the other. The escalation structure described in the label is written for prescribers; the version that applies to you is the one printed on your pharmacy label, and it can differ from the general schedule for reasons specific to your history.

The High-Dose Option Is Newer Than Most Coverage Reflects

The 7.2 mg strength was approved by the FDA on March 19, 2026, which means a great deal of the dose guidance circulating online predates its existence and simply stops at 2.4 mg. If you have read that 2.4 mg is the ceiling, that was accurate for years and is no longer what the label says.

A higher labeled maximum is not an invitation. It expands the range a prescriber can work within for adults who need additional weight reduction, and it does so alongside the same gastrointestinal profile that made the escalation ladder necessary in the first place. Whether a higher strength is appropriate for any individual is a clinical judgment that accounts for tolerability, other conditions and other medications.

The Oral Form Changed the Shape of the Question

Oral semaglutide 25 mg was approved for weight management on December 22, 2025, and it is the first orally administered product in this class approved for that use. Analyses published in Diabetes, Obesity and Metabolism reported that 82.2% of participants treated with oral semaglutide 25 mg in the OASIS 4 trial achieved exposure levels within the same range as participants treated with once-weekly subcutaneous semaglutide 2.4 mg in STEP 1.

That comparison is about drug exposure, not about interchangeability. Oral semaglutide has its own absorption requirements, its own tablet strengths and its own labeled conditions of use, all of which come from the label and the pharmacist rather than from a blog. The practical point for anyone comparing options is that "Wegovy dose" now has two entirely different meanings depending on the formulation.

What the Dose Does and Does Not Predict

The pivotal weight-management evidence for the 2.4 mg injection comes from STEP 1, published in The New England Journal of Medicine, which randomized 1,961 adults with a BMI of 30 or greater — or 27 or greater with at least one weight-related coexisting condition — and without diabetes, to 68 weeks of once-weekly semaglutide 2.4 mg or placebo, plus lifestyle intervention.

Mean body weight change from baseline to week 68 was −14.9% with semaglutide versus −2.4% with placebo. But 86.4% of the semaglutide group achieved at least 5% loss, 69.1% achieved at least 10%, and 50.5% achieved at least 15% — three very different outcomes at the same dose, in the same trial. Dose is one variable in a distribution, not a dial that sets a result.

Where Your Actual Answer Comes From

Every practical question in this territory — which strength, when it changes, what to do about a disruption — resolves to two sources: the label dispensed with your medication and the clinician who wrote the prescription. That is not a deflection. It is where the individualized information legitimately lives, because the label's schedule is written to be modified by a prescriber who knows your tolerability, your other medications and your indication.

Good questions to bring to that conversation are concrete: which indication are we treating, what would make you hold at a strength rather than continue, what should I report and how quickly. Those are answerable by someone with your chart open, and unanswerable by anyone without it.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Oral is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test ($298) to personalize your protocol from day one.

Frequently Asked Questions

What strengths does Wegovy come in?

The current FDA prescribing information lists Wegovy injection as single-dose prefilled pens of 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg and 7.2 mg, and single-dose prefilled syringes from 0.25 mg through 2.4 mg. Wegovy tablets are supplied in 1.5 mg, 4 mg, 9 mg and 25 mg. The 7.2 mg strength, marketed as Wegovy HD, is a pen-only presentation and was approved on March 19, 2026.

Why are there so many different strengths?

The lower strengths exist to support gradual escalation for tolerability rather than because they are treatment targets. The label reports that gastrointestinal adverse reactions were most frequently reported during dosage escalation, with nausea in 44% of patients on the 2.4 mg injection versus 16% on placebo, diarrhea in 30% versus 16%, and vomiting in 24% versus 6%. Escalation is designed to reduce how often those reactions end treatment.

Is 2.4 mg still the maximum dose of Wegovy?

No longer. For years 2.4 mg once weekly was the highest labeled strength, which is why much of the guidance circulating online stops there. The FDA approved the 7.2 mg strength on March 19, 2026, and the current label identifies it as the maximum for additional weight reduction in adults. Whether any higher strength is appropriate for an individual is a clinical judgment made by their prescriber.

How does the tablet form compare with the injection?

Oral semaglutide 25 mg was approved for weight management on December 22, 2025. Published exposure analyses reported that 82.2% of participants treated with oral semaglutide 25 mg in the OASIS 4 trial reached exposure levels within the same range as participants on once-weekly subcutaneous semaglutide 2.4 mg in STEP 1. The milligram numbers are not comparable across formulations because absorption differs substantially.

Does a higher dose mean more weight loss?

Not reliably at the individual level. In STEP 1, which randomized 1,961 adults to 68 weeks of semaglutide 2.4 mg or placebo, mean weight change was −14.9% versus −2.4%. Within that single dose group, 86.4% lost at least 5%, 69.1% lost at least 10% and 50.5% lost at least 15% — a wide distribution at one strength. Dose is one variable among many, not a setting that determines an outcome.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.